US Stock MarketDetailed Quotes
CSCI COSCIENS Biopharma
- 3.950
- +0.110+2.86%
Close Sep 26 16:00 ET
12.31MMarket Cap-1470P/E (TTM)
3.997High3.510Low9.54KVolume3.510Open3.840Pre Close37.11KTurnover0.34%Turnover RatioLossP/E (Static)3.12MShares11.10052wk High0.47P/B11.24MFloat Cap3.49052wk Low--Dividend TTM2.85MShs Float690000.000Historical High--Div YieldTTM12.67%Amplitude3.490Historical Low3.889Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
COSCIENS Biopharma Stock Forum
COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs
TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ:CSCI) (TSX:CSCI) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided an update on the progress of its merger...
U.S. equities ended the trading day with mixed results, reflecting cautious investor sentiment amid ongoing tech stock rotation and the anticipation of potential interest rate cuts by the Federal Reserve. $Dow Jones Industrial Average (.DJI.US)$ closed at a new record high of 41,250.50, up 0.02% (or 9 points). Meanwhile, both the $S&P 500 Index (.SPX.US)$ and $Nasdaq Composite Index (.IXIC.US)$ gained 0.2%.
Key Stock M...
COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
COSCIENS Biopharma Inc. (NASDAQ: CSCI) announced top-line results for its Phase 3 DETECT-trial evaluating macimorelin for diagnosing Childhood Onset Growth Hormone Deficiency (CGHD).
The study did not meet its primary efficacy endpoint as defined in the protocol, despite macimorelin demonstrating its ability to stimulate growt...
No comment yet